Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).

导出原文传递

翻译打印收藏纠错

第一作者： Maeve A,Hennessy

第一单位： Cancer Research @UCC, Cork, Ireland; roisin.connolly@ucc.ie 122108045@umail.ucc.ie.

作者： Maeve A,Hennessy ^[1] ; Jeffrey P,Leal ^[2] ; Chiung-Yu,Huang ^[2] ; Lilja B,Solnes ^[3] ; Rita,Denbow ^[2] ; Vandana G,Abramson ^[2] ; Lisa A,Carey ^[4] ; Minetta C,Liu ^[5] ; Mothaffar,Rimawi ^[6] ; Jennifer,Specht ^[7] ; Anna Maria,Storniolo ^[8] ; Vicente,Valero ^[9] ; Christos,Vaklavas ^[10] ; Eric P,Winer ^[11] ; Ian E,Krop ^[12] ; Antonio C,Wolff ^[12] ; Ashley,Cimino-Mathews ^[2] ; Richard L,Wahl ^[2] ; Vered,Stearns ^[13] ; Roisin M,Connolly ^[2]

作者单位： Cancer Research @UCC, Cork, Ireland; roisin.connolly@ucc.ie 122108045@umail.ucc.ie. ^[1] Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland. ^[2] University of California, San Francisco, California. ^[3] Vanderbilt University, Nashville, Tennessee. ^[4] University of North Carolina, Chapel Hill, North Carolina. ^[5] Mayo Clinic, Rochester, Minnesota. ^[6] Baylor College of Medicine, Houston, Texas. ^[7] University of Washington, Seattle, Washington. ^[8] Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, Indiana. ^[9] M.D. Anderson Cancer Center, Houston, Texas. ^[10] University of Alabama, Birmingham, Alabama. ^[11] Yale Cancer Center, New Haven, Connecticut; and. ^[12] Washington University, St. Louis, Missouri. ^[13]

关键词 FDG PET/CT HER2-positive biomarkers breast cancer neoadjuvant